Annual RAC meeting

Vibishan B.


20163448

8th July, 2021


- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer




- Existing setup for dispersal selection
- Large outbred population of *Drosophila* melanogaster



- Existing setup for dispersal selection
- Large outbred population of *Drosophila* melanogaster

Tradeoffs against dispersal

 Previous work in normal food showed largely <u>cost-free</u> selection response.



- Existing setup for dispersal selection
- Large outbred population of *Drosophila* melanogaster

Tradeoffs against dispersal

- Previous work in normal food showed largely <u>cost-free</u> selection response.
- Could costs be detected in a nutritionally-deprived context?

- Dispersal evolution with the same setup, but with larval malnutrition

- Dispersal evolution with the same setup, but with larval malnutrition

Selection line populations

- MD-Malnourished Dispersers
- MC-Malnourished Control

- Dispersal evolution with the same setup, but with larval malnutrition

Response at generation 42

- Dispersal response seen-MD were more likely to initiate dispersal and dispersed over longer distances than MC.
- Locomotor activity higher in MD than in MC, but no costs in body weight or fecundity

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

 Dispersal selection suspended from March to November 2020 spanning 11 generations

- Dispersal selection suspended from March to November 2020 spanning 11 generations
- Two assays to assess loss of phenotype before continuing selection-dry body weight and locomotor activity


Locomotor activity


Activity (Two-way mixed-effects ANOVA); Population main effect:

$$F_{1,6} = 4.938; p = 0.068$$

Rest (linear mixed-effects binomial model); Population main effect:

$$z = -3.990; p = 6.61e - 05$$






Dry body weight

Three-way mixed-effects ANOVA

Population main effect: $F_{1,150} = 73.186; p = 1.233e - 14$

Sex main effect: $F_{1,150} = 1189.076; p < 2.2e - 16$

Popn-sex interaction: $F_{1.150} = 12.778; p = 0.0004713$



Resuming selection

- Locomotor phenotype is still detectable, body weight trends are unclear.
- About 20 more generations of dispersal have now been carried out-62 generations of selection in total

Resuming selection

- Locomotor phenotype is still detectable, body weight trends are unclear.
- About 20 more generations of dispersal have now been carried out-62 generations of selection in total
- Bigger set of assays need to be repeated-dispersal kernel, body weight and fecundity
- I plan to conduct smaller experiments for the time being-exploration and male-male aggression, and kit-based estimation of total glucose and triglyceride content.

Resuming selection

- Locomotor phenotype is still detectable, body weight trends are unclear.
- About 20 more generations of dispersal have now been carried out-62 generations of selection in total
- Bigger set of assays need to be repeated-dispersal kernel, body weight and fecundity
- I plan to conduct smaller experiments for the time being-exploration and male-male aggression, and kit-based estimation of total glucose and triglyceride content.
- Standardisation-consumption rate based on coloured dye uptake and recording-based approaches to measure time to starvation or dessication

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

Conventional vs adaptive therapy




Figure 1: Drug at maximum dose-competitive release of resistant cells¹



¹ Image courtesy: Harshavardhan BV

Conventional vs adaptive therapy




Figure 1: Drug at maximum dose-competitive release of resistant cells¹




Figure 2: Adaptive therapy and control through competition¹

¹ Image courtesy: Harshavardhan BV

 Early prostate cancer cells-dependent on testosterone supply for growth-treated by chemical castration

- Early prostate cancer cells-dependent on testosterone supply for growth-treated by chemical castration

- Early prostate cancer cells-dependent on testosterone supply for growth-treated by chemical castration
- Other cells become testosterone-independent in growth ⇒ resistant to inhibitors-treatment?

Three cell types and two resources

- Oxygen-externally-supplied resource
- Testosterone-produced internally
- T⁺-testosterone-dependent, but not producing
- T^p-testosterone-dependent, also producing as a public good
- T⁻-testosterone-independent

This work was done with Harsha, a Master's student in the lab.

A mathematical framework

For
$$i \in \{T^+, T^p, T^-\}$$

$$\frac{dy_i}{dt} = r_{i,max} y_i \left(1 - \frac{\sum_j y_j}{1 + K_{i,max} f_i(O_2) f_i(T)}\right) - \delta_i y_i \tag{1}$$

For $R \in \{O_2, T\}$

$$f_{i}(R) = \begin{cases} 1 & \text{if } ul_{R,i} \le R\\ \frac{R - ll_{R,i}}{ul_{R,i} - ll_{R,i}} & \text{if } ll_{R,i} < R < ul_{R,i}\\ 0 & \text{if } R \le ll_{R,i} \end{cases}$$
 (2)

$$\frac{dO_2}{dt} = p_{O_2} - \sum_{i} \mu_{O_2, i} y_i - \lambda_{O_2} O_2$$
 (3)

$$\frac{dtest}{dt} = p_{test}(abi)y_{T^p} - \sum_{i} \mu_{test,i}y_i - \lambda_{test}test$$
 (4)

A mathematical framework






Figure 3: Response function for change in carrying capacity against resource concentration


Parameterisation

Doubling times, consumption rates for oxgen and testosterone, and testosterone production rate for T^p were all derived from literature sources reporting empirical measurements in cell lines.






- Doubling rates scale as $T^- < T^+ < T^p$, but T^- doesn't win by default.
- Resource limitations can be used to tune co-existence.



- Doubling rates scale as $T^- < T^+ < T^p$, but T^- doesn't win by default.
- Resource limitations can be used to tune co-existence.
- Testosterone is the stronger limiting resource in this system.



- Doubling rates scale as T⁻<T⁺<T^p, but T⁻ doesn't win by default.
- Resource limitations can be used to tune co-existence.
- Testosterone is the stronger limiting resource in this system.
- Higher T⁻ proportion makes tumours harder to treat and more unresponsive.

Further development

- A resource-consumer model without explicit carrying capacity terms-parameterisation is ongoing
- Further exploration of therapy parameters in the same model-rules of on and off, frequency, multi-drug combinations
- Spatial dynamics-a discrete reaction-diffusion system is being considered at the moment

All three lines are being developed with undergraduate students from IISER Pune.

- Dispersal selection
 - Work done up to 2020
 - Post-pandemic data and future directions
- Cancer theory
 - Adaptive therapy
 - Other theory work in cancer

- Body size as well as lifespan varies widely across species and taxa.
- Cancer risk is not correlated to this variation (Peto, 2015).

- Body size as well as lifespan varies widely across species and taxa.
- Cancer risk is not correlated to this variation (Peto, 2015).
- Lack of data and multiple disparate lines of theoretical inquiry

- Body size as well as lifespan varies widely across species and taxa.
- Cancer risk is not correlated to this variation (Peto, 2015).
- Lack of data and multiple disparate lines of theoretical inquiry
- How does greater number of cells or cell division cycles not increase risk of mutation and cancer?

- Body size as well as lifespan varies widely across species and taxa.
- Cancer risk is not correlated to this variation (Peto, 2015).
- Lack of data and multiple disparate lines of theoretical inquiry
- How does greater number of cells or cell division cycles not increase risk of mutation and cancer?
- Selection on somatic mutations and clonal expansion are uncommon in current theory (Nowell, 1976).
- Neutral vs non-neutral somatic mutation accumulation

Within species-late-life decline

• Incidence of cancer in humans rises near mid-life, peaks around 70 years and then declines (Harding et al., 2012).

Within species-late-life decline

- Incidence of cancer in humans rises near mid-life, peaks around 70 years and then declines (Harding et al., 2012).
- Reasons for late-life decline in incidence are unclear and links with late-life mortality plateaus are unexplored.
- What roles do temporal patterns of turnover play in mutation accumulation? (Rozhok and DeGregori, 2019)

Within species-late-life decline

- Incidence of cancer in humans rises near mid-life, peaks around 70 years and then declines (Harding et al., 2012).
- Reasons for late-life decline in incidence are unclear and links with late-life mortality plateaus are unexplored.
- What roles do temporal patterns of turnover play in mutation accumulation? (Rozhok and DeGregori, 2019)

Work on developing an agent-based model based on Erten and Kokko (2020) for both these questions is ongoing with a Master's student.

Timeline 1

- Lab change in 2019
- Pandemic and lockdown in 2020
- Multiple lines of active work that would take at least a year to complete

- Erten, E. Y. and Kokko, H. (2020). From zygote to a multicellular soma: Body size affects optimal growth strategies under cancer risk. Evolutionary Applications *13*, 1593–1604.
- Harding, C., Pompei, F. and Wilson, R. (2012). Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer *118*, 1371–1386.
- Nowell, P. (1976). The clonal evolution of tumor cell populations. Science *194*, 23–28.
- Peto, R. (2015). Quantitative implications of the approximate irrelevance of mammalian body size and lifespan to lifelong cancer risk. Philosophical Transactions of the Royal Society B: Biological Sciences *370*, 20150198.
- Rozhok, A. and DeGregori, J. (2019). A generalized theory of age-dependent carcinogenesis. eLife 8, e39950.

Thank you for your attention.